EUCTR2009-014863-37-DK进行中（未招募）1 期
Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tu,our in combination with trastuzumab (Herceptin (R)) in patientswith non-resectable liver metasatses from breast cancerA phase II trial in patients without extrahepatic disease.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Informed consent
- •Age > 18 years
- •Performance status 0-1; expected survival = 3 months
- •Patient with histologically or cytologically confirmed adenocarcinoma of the breast
- •Liver metastases not suitable for local treatment
- •Extrahepatic disease should be excluded by PET-CT-scan.
- •No progression on treatment with capecitabine
- •Prior treatment with taxane (adjuvant or for metastatic disease)
- •Metastatic involvement < 70 % of the liver
- •Neutrophil granulocytes ? 1.5 x 109/l and thrombocytes ? 100 x 109/l
- •Bilirubine ? 2.0 x UNL (upper normal limit)
- •Creatinine-clearence ? 30 ml/min
- •An angiography shows that intrahepatic treatment can be accomplished
- •The treatment is approved by ”Second Opinion udvalget”
- •If the patient is HER2-positive:
- •Baseline LVEF = 50 % (MUGA or echocardiography)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of chemotherapy within the 4-week period prior to the start of trial medication
- •Other current or prior malignant disease except adequately treated and cured carcinoma in situ of the cervix or squamous cell carcinoma of the skin
- •Previous treatment with oxaliplatin
- •Cytotoxic or experimental treatment within a 14 days period before start of trial medication
- •Current participation in other clinical trials
- •Any clinical symptoms suggesting peripheral neuropathy grade 2 or CNS metastases (In case of clinical suspicion on CNS metastases a MR or CT scan must be conducted within 4 weeks before inclusion)
- •Other severe medical conditions e.g. severe cardiovascular disease or AMI < 1 year
- •Medical diseases or condition affecting the patients compliance with peroral study drug
- •Patients with uncontrolled infection
- •Pregnant or lactating women
- •Women capable of childbearing not using a sufficient non-hormonal method of birth control (spiral)
- •Patients who due to physiological, intelectual, cultural reasons, or lack of language capabilities, an unable to comply with the treatment concept or to place the patient at high risk from treatment related complications
- •Prior serious or unsuspected reaction to fluorpyrimidin therapy
- •Known prior hypersensitivity reactions any components used
- •If the patient is HER2-positive:
- •Dyspnoe at rest due to complication of advanced malignancy e.g.lung metastases with lymphangitis or any other conditions necessitating supportive oxygen therapy
研究者
相似试验
进行中（未招募）
不适用
Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine and in patients with a KRAS-wild type tumour in combination with cetuximab in patient with non-resectable liver metastases from cholangiocarcinoma. A phase II trial.Patient with non-resectable liver metastases from cholangiocarcinoma. A phase II trial.MedDRA version: 12.1Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableEUCTR2010-020188-19-DKOncology Department100
进行中（未招募）
1 期
Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®) in patient with non-resectable liver metastases from breast cancer.A phase II trial in patients with limited extrahepatic disease.EUCTR2009-014821-17-DKHerlev Hospital100
招募中
1 期
Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first-line treatment of metastatic colorectal cancer restricted to the liverEUCTR2016-002393-12-BEFédération Francophone de Cancérologie Digestive348
已完成
2 期
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast CancerLiver MetastasesMetastatic Breast CancerNCT01387373Dorte Nielsen14
已完成
2 期
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic DiseaseLiver MetastasesMetastatic Breast CancerNCT01387295Dorte Nielsen38